Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
Shareholders of Catalyst Pharmaceuticals (NASDAQ: CPRX) got a nasty shock on Jan. 23 when the company reported that a competitor, Teva Pharmaceutical Industries (NYSE: TEVA), was planning to make a generic version of its only marketed drug, Firdapse. With Catalyst's shares falling 30% in a day before slightly recovering, it's clear that the market is interpreting Teva's actions as severely threatening, and it's reasonable for investors to wonder if it's time to start looking for the door. Firs...
Updates from bluebird (BLUE) and Catalyst Pharmaceuticals (CPRX) are the key highlights from the biotech sector during the past week.
When the lights went out on 2022, all three major U.S. stock indexes had delivered their worst returns since 2008. While the Nasdaq losing a third of its value in such a short time frame is undoubtedly brutal for short-term traders, it represents a generational opportunity for patient investors to snag high-quality stocks at a discount. The first surefire bargain that has the potential to double your money by mid-decade is brand-name and generic-drug producer Teva Pharmaceutical Industries (NY...
Catalyst Pharmaceuticals (CPRX) receives a notice letter stating that Teva Pharmaceuticals has filed an application to the FDA seeking approval for a generic version of Firdapse.
Teva said Monday it plans to knock off Catalyst's only approved drug and CPRX stock — which has sat atop the IBD 50 for weeks — crashed.
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has received a Notice Letter stating that Teva Pharmaceutical Industries Ltd (NYSE: TEVA) submitted an abbreviated marketing application to the FDA for a generic version of Firdapse in the U.S. In the Notice Letter, Teva states that it intends to market a generic version of Firdapse before the expiration of Catalyst's patents covering U.S. patents expiring up to February 2037. Teva's Notice Letter states that its ANDA contains a Paragraph IV Certificat
TEL AVIV, Israel, January 19, 2023--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its targets to reduce greenhouse gas (GHG) emissions have been approved by the Science Based Targets initiative (SBTi), providing external validation of the Company’s ambitious commitments to minimize its environmental footprint.
While the stock market has performed abysmally over the past 12 months, there are plenty of stocks available at steep discounts. Three Motley Fool contributors were asked to identify dirt cheap stocks to buy in January. Here's why they chose Pfizer (NYSE: PFE), Teva Pharmaceutical Industries (NYSE: TEVA), and Vertex Pharmaceuticals (NASDAQ: VRTX).
TEL AVIV, Israel & PARSIPPANY, N.J., January 12, 2023--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2022 financial results, as well as on its financial guidance for 2023, on Wednesday, February 8, 2023 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
With the required participation from states and local governments, TEVA can now move forward with the nationwide settlement.